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In Brief
The cerebral cavernous malformation
pathway is necessary for cardiovascular
development and to prevent vascular
malformations later in life. How this
pathway regulates endothelial cell
function remains unclear. Zhou et al.
demonstrate that CCM signaling inhibits
the MEKK3 signaling pathway to control
endothelial gene expression during
cardiovascular development.
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The cerebral cavernous malformation (CCM) path-
way is required in endothelial cells for normal cardio-
vascular development and to prevent postnatal
vascular malformations, but its molecular effectors
are not well defined. Here we show that loss of
CCM signaling in endocardial cells results in mid-
gestation heart failure associated with premature
degradation of cardiac jelly. CCM deficiency dramat-
ically alters endocardial and endothelial gene ex-
pression, including increased expression of the Klf2
and Klf4 transcription factors and the Adamts4 and
Adamts5 proteases that degrade cardiac jelly. These
changes in gene expression result from increased
activity of MEKK3, a mitogen-activated protein ki-
nase that binds CCM2 in endothelial cells. MEKK3
is both necessary and sufficient for expression of
these genes, and partial loss of MEKK3 rescues car-
diac defects in CCM-deficient embryos. These find-
ings reveal a molecular mechanism by which CCM
signaling controls endothelial gene expression dur-
ing cardiovascular development that may also un-
derlie CCM formation.
INTRODUCTION
Embryonic heart growth requires the coordinated expansion and
patterning of two major cell types: endothelial cells that line the
lumen of the cardiac chambers, and contractile myocardial
cells that pump blood. These cell types support and interact
with each other through secreted factors, i.e., endocardial-168 Developmental Cell 32, 168–180, January 26, 2015 ª2015 Elsevisecreted growth factors such as neuregulin and fibroblast
growth factors (FGFs) that stimulate myocardial proliferation
(Gassmann et al., 1995; Lavine et al., 2005) and myocardial-
derived factors such as angiopoietin (Jeansson et al., 2011)
that support endocardial growth. Loss of endocardial-myocar-
dial signaling results in a failure of cardiac growth and embryonic
lethality (Gassmann et al., 1995). Similar phenotypes arise in hu-
man patients with cardiac non-compaction (Jenni et al., 1999).
During the early, most rapid period of cardiac growth (embry-
onic day 8.5 [E8.5]–E14.5 in the mouse), abundant extracellular
matrix known collectively as cardiac jelly separates the endocar-
dium and myocardium (Nakamura and Manasek, 1981). Cardiac
jelly consists of glycoaminoglycans such as hyaluronic acid (HA),
and HA-binding proteins such as versican. Loss of either HA
synthase or versican results in a thin myocardium that fails to
proliferate and form normal trabeculae (Camenisch et al., 2000;
Yamamura et al., 1997). As the heart matures and trabeculation
is completed, cardiac jelly is lost and myocardial proliferation
slows. Recent genetic studies in mice have implicated endocar-
dial expression of secreted proteases such as ADAMTS1 and
ADAMTS5 that degrade versican in the regulation of cardiac jelly
and heart valve formation (Dupuis et al., 2011; Stankunas et al.,
2008), but the upstream signaling pathways that control endo-
thelial expression of such proteases and thereby regulate car-
diac growth remain largely unknown.
The cerebral cavernous malformation (CCM) signaling path-
way was discovered through genetic studies of human patients
with familial vascular malformations (Chan et al., 2010; Riant
et al., 2010). These studies have identified loss of function muta-
tions in three genes, KRIT1, CCM2, and PDCD10 (reviewed in
Riant et al., 2010) that encode intracellular adaptor proteins
that associate to form a biochemical complex with the trans-
membrane protein Heart of Glass (HEG1) (Kleaveland et al.,
2009; Zheng et al., 2010). Conditional deletion studies in mice
have demonstrated that KRIT1 and CCM2 are required iner Inc.
endothelial cells for branchial arch artery formation at E8.5–E9
(Whitehead et al., 2004, 2009; Zheng et al., 2010), and to prevent
CCM formation in the CNS of postnatal animals (Boulday et al.,
2011; Chan et al., 2011; McDonald et al., 2011). How CCM
signaling regulates endothelial and vascular function remains un-
clear. Cell culture studies and pharmacologic studies in mice
have linkedCCMsignaling to negative regulation of RhoA activity
(Glading et al., 2007; Stockton et al., 2010; Whitehead et al.,
2009; Zheng et al., 2010) and TGFb (Maddaluno et al., 2013),
but definitive evidence for a causal relationship to these path-
ways or other downstream CCM effectors that clearly explain
the pathway’s function in vascular development and mainte-
nance has been lacking.
A role for CCM signaling in the developing heart was first
revealed by zebrafish embryos lacking heg1, krit1, ccm2, and
pdcd10 that exhibited a characteristic dilated heart phenotype
(Mably et al., 2003, 2006; Zheng et al., 2010). In the developing
mouse, Heg is strongly expressed in the endocardium and its
loss results in patchy areas of thin myocardium and cardiac
rupture in late gestation (Kleaveland et al., 2009; Zheng et al.,
2012). We have also recently identified a CCM2 ortholog,
CCM2L, that is expressed selectively in the endocardium of the
developing heart where it regulates cardiac growth (Zheng
et al., 2012). A major impediment to defining the role of the
CCM pathway in cardiac development in mice has been early
lethality due to vascular defects that prevent blood circulation.
In the present study, we use an Nfatc1Cre allele to delete CCM
pathway genes specifically in the endocardium and bypass this
vascular requirement (Wu et al., 2012). We find that loss of endo-
cardial CCM signaling results in embryonic heart failure and
reduced myocardial growth that is characterized by loss of car-
diac jelly and preserved expression of endocardial growth factors.
This phenotype is caused by increased expression of theKlf2 and
Klf4 transcription factors and the Adamts4 and Adamts5 prote-
ases that degrade the cardiac jelly protein versican. CCM-defi-
cient endothelial gene expression changes are associated with
increased activity of the MEKK3 signaling pathway, and CCM-
deficient changes in cultured endothelial cells and embryonic
mouse and fish hearts are rescued by reduced MEKK3 expres-
sion or activity. These studies define regulation of MEKK3 sig-
naling and endothelial gene expression as a conserved mecha-
nism by which CCM signaling functions in the developing heart,
and raise the possibility that loss of this molecular regulatory
mechanism may also participate in CCM formation.
RESULTS
Nfatc1Cre Drives Recombination in the Endocardium
but Not in the Endothelium of Developing BAAs
or Peripheral Vessels
Previous studies of global and endothelial-specific loss of Krit1
and Ccm2 revealed embryonic lethality at E8.5–E9.5 due to a
lack of lumenized branchial arch arteries (BAAs) and blood circu-
lation (Boulday et al., 2009; Whitehead et al., 2004, 2009; Zheng
et al., 2010), a severe vascular phenotype that was also
observed in zebrafish embryos lacking HEG-CCM signaling
(Zheng et al., 2010). Cardiac defects, such as atrial enlargement,
reduced trabeculation, and pericardial edema, were noted in
deficient mouse embryos (Boulday et al., 2009; WhiteheadDevelopmet al., 2004), but because these changes arose in animals with
complete vascular disruption, it was not clear if they were pri-
mary or secondary phenotypes.
To circumvent the early requirement for CCM signaling in
the BAA endothelium and investigate the role of CCM signaling
specifically in the heart, we used Nfatc1Cre mice (Wu et al.,
2012). Consistent with published studies, lineage tracing
studies inNfatc1Cre;R26R-YFP animals revealedNfatc1Cre activ-
ity throughout the atrial and ventricular endocardium, but not in
the endothelium of the distal aortic sac or the developing BAAs
at E10.5 (Figures S1A–S1F available online). Nfatc1Cre activity
was observed in endothelial cells of the ascending aorta and
proximal pulmonary arteries at E14.5, but not in more distal great
vessels at that time point (Figures S1G–S1K) or in the endothelial
cells of the peripheral vasculature in the liver or kidney at P1 (Fig-
ures S1L–S1R). These studies suggested thatNfatc1Cre could be
used to test the requirement for CCM signaling specifically within
the endocardium of the developing heart.
Endocardial Deletion of Krit1 Results in Mid-Gestation
Heart Failure Associated with Loss of Cardiac Jelly
Analysis of Nfatc1Cre;Krit1fl/+ 3 Krit1fl/fl crosses at postnatal day
0.5 (P0.5) revealed that Nfatc1Cre;Krit1fl/fl mice die prior to birth
(Table S1). Timed matings demonstrated live Nfatc1Cre;Krit1fl/fl
embryos that were grossly indistinguishable from littermate con-
trols at E12.5 (Figure S2), but all Nfatc1Cre;Krit1fl/fl embryos were
dead by E14.5–-E15.5 (Figure S2 and Table S1). Thus endocar-
dial loss of KRIT1 results in embryonic lethality during mid-
gestation.
To understand the cause of lethality, Nfatc1Cre;Krit1fl/fl and
control littermates were examined at E10.5 and E12.5, time
points prior to lethality. Hematoxylin and eosin staining (H&E)
of Nfatc1Cre;Krit1fl/fl hearts at E10.5 revealed thin myocardium
and smaller myocardial trabeculae compared with littermate
controls, despite the presence of abundant endocardial cells
(Figures 1A and 1B). These changes were more marked at
E12.5, when control hearts had developed a thicker compact
myocardium and well-developed trabeculae (Figures 1C and
1D). Atrial and ventricular chamber dilatation, like that observed
in ccm-deficient zebrafish embryos (e.g., Figure 4 and Mably
et al., 2003, 2006), were also observed in Nfatc1Cre;Krit1fl/fl em-
bryos at E12.5 (e.g., Figure 1C versus Figure 1D). Most striking
was the reduction in space between the endocardium and
myocardium that is occupied by cardiac jelly in Nfatc1Cre;
Krit1fl/fl embryo hearts at E10.5 and E12.5 (Figures 1A–1D).
This phenotype was particularly evident in the trabeculae, where
the myocardium was wrapped tightly by endocardium in the
Nfatc1Cre;Krit1fl/fl heart but clearly separated from the endocar-
dium in control hearts at these time points (arrows, Figures 1A–
1D). Quantitation of the area occupied by cardiac jelly in
the trabeculae of the E10.5 heart revealed a >65% decrease
in Nfatc1Cre;Krit1fl/fl hearts compared with either Krit1fl/fl or
Nfatc1Cre;Krit1fl/+ littermate hearts (Figure 1E).
The loss of endocardial-myocardial separation in Nfatc1Cre;
Krit1fl/fl hearts suggested that endocardial loss of CCM1 results
in reduced cardiac matrix/jelly. Consistent with this observation,
Alcian blue staining demonstrated loss of matrix glycosamino-
glycans in the Nfatc1Cre;Krit1fl/fl heart, particularly surrounding
the trabeculae at E10.5 (Figures 1F and 1G). Versican is themajorental Cell 32, 168–180, January 26, 2015 ª2015 Elsevier Inc. 169
Figure 1. Lack of Endocardial Krit1 Results
in Loss of Cardiac Jelly
(A–D) Nfatc1Cre;Krit1fl/fl hearts exhibit thinned
myocardium and reduced space between endo-
cardial and myocardial cells at E10.5 and E12.5.
Arrows indicate the endocardial-myocardial gap.
(A0-D0) Higher magnification images of the regions
boxed in (A)–(D).
(E) Ratio of the area occupied by cardiac jelly to
that occupied by myocardium in the trabeculae of
E10.5 littermate hearts. N = 3 embryos; nine sec-
tions analyzed for each group. **p < 0.01. Error
bars represent SEM.
(F and G) Reduced Alcian blue staining in
Nfatc1Cre;Krit1fl/fl hearts at E10.5. (F0 and G0)
Higher magnification images of the regions boxed
in (F) and (G).
(H and I) Immunostaining for versican in
Nfatc1Cre;Krit1fl/fl and control hearts at E10.5. (H0
and I0) Higher magnification images of the regions
boxed in (H) and (I). Scale bars represent 100 mm.protein component of cardiac jelly, and loss of versican results in
reduced myocardial growth and failure to form myocardial
trabeculae. Immunostaining revealed a severe loss of intact ver-
sican in the E10.5Nfatc1Cre;Krit1fl/fl heart comparedwith controls
(Figures 1H and 1I). Thus endocardial loss of KRIT1 results in
mid-gestation heart failure associated with reduced cardiac jelly.
Endocardial Loss of Ccm2 and Pdcd10 Also Results in
Loss of Cardiac Jelly
In the CCM signaling pathway, KRIT1 binds CCM2 and CCM2
binds PDCD10 to form a ternary complex (Hilder et al., 2007; Za-
wistowski et al., 2005; Zhang et al., 2007), and deficiency of any of
these three proteins results in CCM formation in human patients
and inmousemodels of postnatal endothelial deficiency (Boulday170 Developmental Cell 32, 168–180, January 26, 2015 ª2015 Elsevier Inc.et al., 2009, 2011; Whitehead et al., 2004,
2009). However, KRIT1 also regulates in-
tegrin affinity through its interaction with
ICAP1 (Liu et al., 2013) and binds RAP1
(Serebriiskii et al., 1997). Thus, the role of
KRIT1 in the endocardium of the devel-
oping heart might not simply reflect the
role for CCM signaling in that cell type.
To test whether the cardiac abnormalities
described above arise due to loss of ca-
nonical CCM signaling in the endocar-
dium, we deleted Ccm2 and Pdcd10
in the endocardium using Nfatc1Cre.
Nfatc1Cre;Ccm2fl/fl embryos exhibited em-
bryonic lethality at the same time point as
observed for Nfatc1Cre;Krit1fl/fl embryos
(Table S1). Nfatc1Cre;Ccm2fl/fl embryos
also exhibited similar reductions in car-
diac jelly, myocardial growth, Alcian blue
staining, and cardiac versican at both
E10.5 (Figures 2A–2F) and E12.5 (Figures
2G–2L). Nfatc1Cre;Pdcd10fl/fl embryos ex-
hibited embryonic lethality that was later
than that as observed for Nfatc1Cre;Krit1fl/fl and Nfatc1Cre;Ccm2fl/fl embryos (Table S1). Nfatc1Cre;
Pdcd10fl/fl embryos did not appear abnormal at E10.5, but
reduced cardiac jelly, myocardial growth, Alcian blue staining,
and versicanwere observed at E12.5 (Figures 2M–2R), consistent
with a milder presentation of the same phenotype. These findings
suggest that all three primary components of the CCM signaling
pathway function in the mid-gestation endocardium to maintain
cardiac jelly and support cardiac growth.
Endocardial Loss of KRIT1 Is Associated with Changes
in the Expression of KLF2/4 Transcription Factors and
ADAMTS4/5 Proteases
The thin myocardium and reduced cardiac jelly observed in
Nfatc1Cre;Krit1fl/fl hearts could result from reduced endocardial
Figure 2. Endocardial Loss of Ccm2 or
Pdcd10 Also Results in Reduced Cardiac
Jelly
(A and B) Thin myocardium and reduced endo-
cardial-myocardial space in Nfatc1Cre;Ccm2fl/fl
hearts at E10.5. (A0 and B0) Higher magnification
images of the regions boxed in (A) and (B). (B) Error
bars represent SEM.
(C and D) Reduced Alcian blue staining in
Nfatc1Cre;Ccm2fl/fl hearts at E10.5. Error bars
represent SEM.
(E and F) Reduced intact versican in in
Nfatc1Cre;Ccm2fl/fl hearts at E10.5.
(G and H) Thin myocardium and reduced endo-
cardial-myocardial space in Nfatc1Cre;Ccm2fl/fl
hearts at E12.5. (G0 and H0) Higher magnification
images of the regions boxed in (G) and (H).
(I and J) Reduced Alcian blue staining in
Nfatc1Cre;Ccm2fl/fl hearts at E12.5. (J) Error bars
represent SEM.
(K and L) Reduced intact versican in in
Nfatc1Cre;Ccm2fl/fl hearts at E12.5. (K) Error bars
represent SEM.
(M and N) Thin myocardium and reduced endo-
cardial-myocardial space in Nfatc1Cre;Pdcd10fl/fl
hearts at E12.5. (M0 and N0) Higher magnification
images of the regions boxed in (M) and (N).
(O and P) Reduced Alcian blue staining in
Nfatc1Cre; Pdcd10fl/fl hearts at E12.5.
(Q and R) Reduced intact versican in in Nfatc1Cre;
Pdcd10fl/fl hearts at E12.5. Scale bars represent
100 mm.expression of myocardial growth factors and components of the
cardiac jelly such as hyluronic acid. Alternatively, endocardial
CCM signaling might be required to prevent the expression
of proteases such as those in the ADAMTS family that cleave
versican and degrade cardiac jelly at later time points during
cardiac development (Stankunas et al., 2008; Dupuis et al.,
2011). To address these possible mechanisms we character-
ized gene expression in whole E10.5 Nfatc1Cre;Krit1fl/fl and litter-
mate control hearts using microarray and qPCR analysis. Micro-
array and qPCR analysis revealed elevated levels of Adamts4
and Adamts5, versican-degrading proteases, in addition to
Klf2 and Klf4 and a number of known KLF2/4 target genes,
including Nos3, Aqp1, Jam2, Thbd, and Palmd (Dekker et al.,
2006; Parmar et al., 2006) (Figures 3A, 3B, and 3D). Reduced
levels of Dll4 and Tmem100, genes previously associated withDevelopmental Cell 32, 168–180myocardial growth and trabeculation
(Grego-Bessa et al., 2007; Somekawa
et al., 2012), were also detected (Figures
3A and 3C). Expression of the myocardial
growth factors FGF9, FGF12 and FGF16
(Lavine et al., 2005) was unaltered, while
that of neuregulin was elevated in E10.5
Nfatc1Cre;Krit1fl/fl hearts (Figure 3C), indi-
cating that reduced myocardial growth
did not result from reduced endocardial
expression of growth factors. The ex-
pression of Versican and HA synthase
were also unchanged, despite the dra-matic loss of versican protein detected in Nfatc1Cre;Krit1fl/fl
hearts (Figure 3D). In situ hybridization confirmed the increase
in Klf2 mRNA in the E10.5 Nfatc1Cre;Krit1fl/fl heart (Figure 3E).
KLF4 protein was not detected in the endocardium of the heart
chamber in control animals at E10.5, but was present in the
nuclei of almost all the endocardial cells in the E10.5 Nfatc1Cre;
Krit1fl/fl heart (Figure 3F). Increased levels of KLF2 protein were
also detected by western blot analysis of the E10.5 Nfatc1Cre;
Krit1fl/fl heart (Figure 3G). Significantly, similar changes in Klf
and Adamts gene expression were observed in the E11.5
Nfatc1Cre;Pdcd10fl/fl heart (Figure S2), consistent with a require-
ment for canonical CCM signaling in the regulation of these
genes.
The gene expression studies described above suggested that
excess ADAMTS4/5 activity might be the cause of reduced, January 26, 2015 ª2015 Elsevier Inc. 171
Figure 3. Loss of CCM Signaling Results in
Increased Klf2 and Adamts5 Expression
and Function
(A) Microarray analysis of mRNA expression in
E10.5 Nfatc1Cre;Krit1fl/fl and Krit1fl/+ littermate
hearts reveals increased levels of Klf2, Klf4, KLF2
target genes and Adamts5, and reduced levels of
Dll4 and Tmem100. N = 4 for both genotypes.
(B) qPCR of E10.5 hearts reveals preserved or
increased expression of Nrg1 and FGF growth
factors following endocardial Krit1 loss.
(C) qPCR of E10.5 hearts reveals elevated levels of
Klf2 and established KLF2 target genes following
endocardial Krit1 loss.
(D) qPCR analysis of genes associated with car-
diac jelly matrix proteins and matrix-degrading
proteases in E10.5 hearts reveals elevated levels
of Adamts5 following endocardial Krit1 loss. N = 3
for Krit1fl/fl, N = 4 for Nfatc1Cre;Krit1fl/+, N = 5 for
Nfatc1Cre;Krit1fl/fl in (B)–(D).
(E) In situ hybridization for Klf2 in E10.5
Nfatc1Cre;Krit1fl/fl and Krit1fl/fl littermate hearts.
(F) Immunostaining for KLF4 protein (arrows) and
myocardium (MF20) in E10.5 Nfatc1Cre;Krit1fl/fl
and Krit1fl/fl littermate hearts.
(G) Immunoblot analysis of KLF2 protein in whole
E10.5 Nfatc1Cre;Krit1fl/fl and Nfatc1Cre;Krit1fl/+ and
Krit1fl/fl littermate hearts. GAPDH is shown as a
loading control.
(H) Immunostaining using anti-DPEAAE antibody
to detect ADAMTS-cleaved versican reveals
increased levels in the E10.5 Nfatc1Cre;Krit1fl/fl
heart. Boxed regions are shown at higher magni-
fication on the right.
(I) Immunoblot analysis of lysate derived from
whole E10.5 hearts reveals increased levels of
cleaved versican (DPEAAE) and the ADAMTS5
protease with endocardial loss of Krit1. GAPDH is
shown as a loading control. Scale bars represent
100 mm. *p < 0.05; **p < 0.01; ***p < 0.001.versican and cardiac jelly in Nfatc1Cre;Krit1fl/fl hearts. To
detect ADAMTS-mediated breakdown of versican, we stained
Nfatc1Cre;Krit1fl/fl and control E10.5 hearts with antibodies that
specifically recognize a versican epitope that is exposed
following cleavage by ADAMTS proteases (‘‘DPEAAE’’ antibody)
(Sandy et al., 2001). Despite the nearly complete loss of intact
versican (Figures 1H and 1I), increased levels of ADAMTS-
cleaved versican were detected in the E10.5 Nfatc1Cre;Krit1fl/fl
heart by immunostaining with DPEAAE antibody (Figure 3H).
Biochemical analysis of whole E10.5 Nfatc1Cre;Krit1fl/fl hearts
confirmed a marked increase in the levels of cleaved versican
and ADAMTS5 protease (Figure 3I). These findings tie the loss
of cardiac jelly associated with endocardial loss of CCM
signaling to changes in endocardial gene expression.
Loss of klf2 or adamts5 Rescues Loss of CCM Signaling
in Zebrafish Embryos
Endocardial-specific loss of CCM signaling in the mouse results
in a thin, dilated heart that lacks cardiac jelly/matrix (Figures 1
and 2). This phenotype resembles the dilated heart in zebrafish
embryos lacking this pathway (Mably et al., 2003, 2006), sug-172 Developmental Cell 32, 168–180, January 26, 2015 ª2015 Elsevigestive of a conserved role for CCM signaling in vertebrate car-
diac development. To determine if loss of CCM signaling results
in loss of cardiac jelly/matrix in developing fish as well as mice
we analyzed sections of 72 high-power field (hpf) ccm2 mutant
and control littermate hearts using H&E and Alcian blue staining.
Control hearts exhibited a multicellular layer of myocardium,
with detectable Alcian blue-stained cardiac jelly between the
endocardial and myocardial cell layers (Figures 4A–4C). In
contrast, ccm2 mutant hearts exhibited a thin, single-cell layer
of myocardium, and no Alcian blue staining was detected in
sections that sampled the entire heart (Figures 4D–4F, N = 4
embryos studied for each genotype). Thus, CCM signaling defi-
ciency results in the loss of cardiac jelly in both fish and mouse
embryos, consistent with a conserved role for this pathway dur-
ing heart development.
Molecular analysis of E10.5 Nfatc1Cre;Krit1fl/fl and E10.5
Nfatc1Cre;Pdcd10fl/fl mouse hearts revealed significant upregu-
lation of Klf2/4 and Adamts4/5 gene expression, suggesting
that these genes might play causal roles in the cardiac pheno-
type. To functionally test a conserved role for regulation of
KLF2 and ADAMTS5 by CCM signaling, we next studied 72 hpfer Inc.
Figure 4. Loss of klf2 or adamts5 Rescues
the Cardiac Phenotype Conferred by Loss
of CCM Signaling in Zebrafish Embryos
(A–C) H&E and Alcian blue staining of adjacent
sections from a 72 hpf control zebrafish heart
reveal amyocardial wall withmultiple cell layers (A)
and the presence of Alcian blue-staining cardiac
jelly (B and C).
(D–F) H&E and Alcian blue staining of adjacent
sections from a 72 hpf ccm2 mutant heart reveals
a thin myocardial wall (D) and lack of cardiac jelly
(E and F). (C and F) Higher magnification images of
the boxed regions in (B) and (E).
(G) Injection of zebrafish embryos with krit1 mor-
pholinos results in a big heart at 72 hpf detected by
light microscopy and in i-fabp:GFP transgenic
embryos in which the heart is fluorescently
labeled.
(H) Injection of morpholinos targeting both krit1
and the two klf2 zebrafish orthologs rescues the
big heart phenotype at 72 hpf.
(I) Injection of morpholinos targeting both krit1
and adamts5 rescues the big heart phenotype at
72 hpf.
(J) Efficiency of rescue of the krit1 morphant heart
phenotype with klf2 and adamts5 morpholinos.
***p < 0.001.
(K) Knockdown of klf2 or adamts5 also rescues the
cardiac phenotype in ccm2 mutant zebrafish em-
bryos. The frequency of a big heart phenotype in
the offspring of ccm2+/ intercrosses treated with
control, klf2 or adamts5 morpholinos is shown.
**p < 0.01; *p < 0.05. The number of total embryos
analyzed and number experimental repeats (in
parentheses) in (J) and (K) are indicated above
each bar. Scale bars represent 100 mm.zebrafish embryos following injection of morpholinos to block
expression of krit1, with or without co-injection of morpholinos
to block klf2a and klf2b (the two zebrafish Klf2 orthologs) or
adamts5 (the sole zebrafish Adamts5 ortholog). krit1 morpholi-
nos resulted in a dilated heart in approximately 80% of embryos
at 72 hpf (Figures 4G and 4J). When combined with low dose
klf2a/b morpholinos (1.5 ng each) that resulted in a reduction
of approximately 50% in klf2 dosage (Figure S3), we observed
highly efficient rescue of the big heart phenotype (approximately
90% rescue efficiency, p < 0.001) (Figures 4H and 4J). Co-injec-
tion of morpholinos targeting the exon 2 splice acceptor and
donor sites of adamts5 (5+1 ng, a combination chosen to mini-
mize morpholino dose and toxicity, Figures S4C and S4D) also
resulted in a significant rescue of the big heart phenotype
(approximately 50% rescue efficiency, p < 0.001) (Figures 4I
and 4J). To ensure that rescue was not merely due to interfer-
ence with krit1 morpholinos, klf2 or adamts5 morpholinos were
injected into embryos generated by ccm2+/ intercrosses. As
expected, a big heart phenotype was observed in approximately
25% of control offspring at 72 hpf (Figure 4K). However, this car-
diac phenotype was observed in only 7% and 16% of offspring
injected with klf2a/b or adamts5 morpholinos, respectively
(indicative of a 70% and 35% rescue efficiency for klf2 and
adamts5, respectively; p < 0.01 and p < 0.05) (Figure 4K). TheDevelopmlower efficiency of mutant rescue compared with morphant
rescue most likely reflects the greater loss of CCM signaling in
ccm2/mutants compared with krit1morphants. These studies
suggest that a critical and conserved role of CCM signaling in the
developing heart is to negatively regulate the expression of Klf2
and Adamts5.
MEKK3 Regulates KLF and ADAMTSGene Expression in
Cultured Endothelial Cells and in Embryonic
Endocardium
The findings described above revealed that CCMsignaling nega-
tively regulates Klf2 and Adamts5 gene expression, but studies
of signaling by the CCM adaptor proteins have not defined a
transcriptional mechanism of action. How are these pathways
linked? MEKK3 was identified as a CCM2 binding partner a
decade ago (Uhlik et al., 2003), and MEKK3 signaling is known
to regulate gene expression through downstream effectors
such as ERK5 and MEF2C (Chao et al., 1999; Nakamura and
Johnson, 2003), as well as p38 and JNK (Deacon and Blank,
1999; Nebreda and Porras, 2000). We therefore next explored
the possibility that CCM signaling might alter expression of
KLF2 and ADAMTS5 through effects on the MEKK3 pathway.
Because available anti-CCM2 antibodies are unable to detect
the protein in cultured endothelial cells, to determine if MEKK3ental Cell 32, 168–180, January 26, 2015 ª2015 Elsevier Inc. 173
Figure 5. MEKK3 Regulates Expression of
KLF and ADAMTS Genes in Cultured Endo-
thelial Cells and in the Endocardium of the
Developing Heart
(A) Tetracycline-regulated expression of BirA-
MEKK3 drives dose-dependent expression of
KLF2 and KLF4 in HUVEC.
(B) siRNA knockdown ofMEKK3 in HUVEC blocks
flow-induced expression of KLF2, KLF4 and
ADAMTS4. HUVEC were exposed to 16 hr of
laminar shear after exposure to siRNA directed
against MEKK3 (MAP3K3) or control, scrambled
siRNA. N = 5; p < 0.0001.
(C) qPCR of E10.5 hearts reveals severely reduced
levels of Klf2, Klf4 and known KLF2/4 target genes
following endocardial Mekk3 (Map3k3) deletion.
N = 3 for all groups.
(D) qPCR of E10.5 hearts reveals reduced levels of
Nrg1 and Adamts5 but normal levels of FGFs
following endocardial Mekk3 (Map3k3) deletion.
N = 3 for all groups.
(E) qPCR of E9.5 wild-type mouse hearts following
24 hr incubation in medium containing the MEK5
inhibitor BIX02188 (‘‘BIX’’) or DMSO (‘‘control’’).
N = 3 for all groups. Error bars represent SEM. *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.interacts with CCM proteins in endothelial cells we used tetracy-
cline-regulable lentiviral vectors to express an BirA-MEKK3
fusion protein in hCMEC/D3 endothelial cells (Weksler et al.,
2005) (Figure S4). Using this approach, MEKK3-interacting pro-
teins were biotinylated in live endothelial cells (Roux et al., 2012).
Biotinylated proteins were captured by streptavidin beads and
subjected to mass spectrometry analysis. When BirA-MEKK3
was expressed at endogenous levels (4 ng/ml doxycycline, Fig-
ure S4A), no specific MEKK3-interacting proteins were identified
(not shown), perhaps due to kinase inactivity. At slightly higher
expression levels (8 ng/ml doxycycline) peptides from only four
interacting proteins were identified (Figure S4). The most abun-
dant of these was CCM2 (Figure S4E). KRIT1 was also detected
at a lower level equivalent to that of TRAF7, an MEKK3-interact-
ing protein previously identified using tandem affinity purification
(Bouwmeester et al., 2004). A similar result was obtained when
BirA-MEKK3 was expressed in primary human umbilical vein
endothelial cells (HUVECs; Figure S4F). These studies indicate174 Developmental Cell 32, 168–180, January 26, 2015 ª2015 Elsevier Inc.that MEKK3 interacts with the CCM pro-
tein complex in live endothelial cells.
To determine if MEKK3 regulates en-
dothelial gene expression in a manner
that might explain the changes observed
following loss of CCM signaling, we next
tested whether MEKK3 is sufficient and/
or required for KLF and ADAMTS gene
expression in cultured endothelial cells.
Overexpression of MEKK3 using the
doxycycline regulable system described
above resulted in dose-dependent in-
creases in the levels of KLF2 and KLF4
expression in hCMEC/D3 endothelial
cells (Figure 5A). To determine whetherMEKK3 regulates KLF gene expression in response to more
physiologic stimuli, we tested the role of MEKK3 in endothelial
responses to fluid flow. Flow and fluid shear forces are estab-
lished regulators of KLF2 and KLF4 expression in endothelial
cells ex vivo (Huddleson et al., 2004; Parmar et al., 2006; Sohn
et al., 2005; Villarreal et al., 2010) and in humans (Dekker et al.,
2006), mice (Dekker et al., 2006; Lee et al., 2006), chick (Groe-
nendijk et al., 2005), and fish (Vermot et al., 2009) in vivo. Upre-
gulation of KLF2 in response to flow has been shown to bemedi-
ated by MEK5-ERK5 signaling (Li et al., 2008; Parmar et al.,
2006), one of the pathways directly regulated by MEKK3(Chao
et al., 1999; Nakamura and Johnson, 2003). Consistent with prior
studies (Parmar et al., 2006; Sohn et al., 2005), HUVECs exposed
to laminar shear for 16 hr exhibited increased KLF2, KLF4 and
ADAMTS4 expression (Figure 5B). Transfection with siRNAs
directed against MEKK3 that resulted in a 40% knockdown in
MEKK3 expression blocked the rise in expression of KLF2,
KLF4, and ADAMTS4 induced by flow (Figure 5B). These studies
Figure 6. Loss of MEKK3 Rescues the
CCM-Deficient Phenotype in Cultured
Endothelial Cells and Zebrafish Embryos
(A) siRNA knockdown of CCM2 increases the level
of phospho-ERK5 in cultured HUVEC.
(B–D) siRNA knockdown of CCM2 increases
the expression of KLF2, KLF4, and ADAMTS4 in
HUVEC, and these changes in gene expression
are reversed by siRNA knockdown of MEKK3
(MAP3K3). Error bars represent SEM.
(E and F) Injection of zebrafish embryos with krit1
morpholinos results in a big heart at 72 hpf in i-
fabp:GFP transgenic embryos in which the heart is
fluorescently labeled.
(G) Injection of morpholinos targeting both krit1
and map3k3 rescues the big heart phenotype at
72 hpf.
(H) Efficiency of rescue of the krit1 morphant heart
phenotype with map3k3 morpholinos. ***p <
0.001.
(I) Knockdown of map3k3 rescues the cardiac
phenotype in ccm2 mutant zebrafish embryos.
The frequency of a big heart phenotype in the
offspring of ccm2+/ intercrosses treated with
control or map3k3 morpholinos is shown. ***p <
0.001. The number of total embryos analyzed and
number experimental repeats (in parentheses) are
indicated above each bar in (H) and (I); Error bars
represent SEM. Scale bars represent 100 mm.reveal that KLF and ADAMTS expression are regulated by
MEKK3 in cultured endothelial cells.
To determine whether MEKK3 also regulates these genes in
the E10.5 heart, we next generated Nfatc1Cre;Map3k3fl/
animals. Nfatc1Cre;Map3k3fl/ animals did not survive to birth,
and timed matings revealed embryonic lethality prior to E12.5
(Table S1). Analysis of Nfatc1Cre;Map3k3fl/ embryonic heart
sections revealed a thin myocardial cell layer with preserved
cardiac jelly and normal endocardial-myocardial separation at
E10.5 (Figure S5A). In contrast to endocardial loss of CCM sig-
naling, versican levels were preserved in the E10.5 Nfatc1Cre;
Map3k3fl/ heart (Figure S5B). Gene expression analysis of
E10.5 Nfatc1Cre;Map3k3fl/ and control littermate hearts re-
vealed severe (>90%) reductions in the expression of Klf2
and the known KLF2 target genes Nos3, Aqp1, Jam2, Thbd,
and Palmd, as well as Klf4, Adamts4, and Adamts5 (Figures
5C and 5D). FGF gene expression was unchanged but the
expression of Nrg1 was severely reduced (Figure 5D). Thus,
loss of MEKK3 confers gene expression changes that are pre-
cisely reciprocal to those conferred by loss of KRIT1 or
PDCD10. To determine whether MEKK3 regulates Klf and
Adamts gene expression through the ERK5 MAPK pathway,
we cultured wild-type E10.5 explanted hearts in the presence
of BIX02189, a highly specific inhibitor of MEK5, the MAPK2K
that is activated by MEKK3 and in turn activates ERK5 (TatakeDevelopmental Cell 32, 168–180et al., 2008). Treatment with BIX02189
resulted in reduced levels of Klf2, Klf4,
and Adamts5 expression (Figure 5E).
These findings demonstrate that
MEKK3 regulates KLF and ADAMTS
gene expression in endothelial cellsex vivo and in endocardial cells in vivo through the MEK5-
ERK5 MAPK pathway.
Loss of MEKK3 Rescues Loss of CCM Signaling in
Cultured Endothelial Cells and Zebrafish Embryo Hearts
The reciprocal changes in gene expression observed with endo-
cardial loss of CCM and MEKK3 signaling, the physical in-
teraction between the CCM complex and MEKK3, and the
preservation of Mekk3 gene expression in Nfatc1Cre;Krit1fl/fl
hearts (Figure S6A) suggested that CCM signalingmight regulate
endocardial gene expression by inhibiting MEKK3 function. To
test the effect of loss of CCM signaling on MEKK3 function, we
used siRNA to knockdown CCM2 in HUVECs and examined
downstream MEKK3 signaling through ERK5. HUVECs treated
with CCM2 siRNA, but not with scrambled siRNA, exhibited
increased phospho-ERK5 with no change in total ERK5 or
GAPDH protein (Figure 6A), consistent with an increase in
MEKK3 pathway activity. As observed with endocardial deletion
in the E10.5 mouse heart, loss of CCM2 in HUVEC conferred
increased expression of KLF2, KLF4, and ADAMTS4 (Figures
6B–6D). These increases were reversed by simultaneous knock-
down of MEKK3, consistent with CCM regulation of gene
expression through MEKK3.
To test whether increased MEKK3 signaling is causal for
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to reduce the levels ofmekk3 in krit1morphant and ccm2mutant
zebrafish embryos. krit1 morpholinos resulted in a dilated heart
in approximately 65% of embryos at 72 hpf in these studies (Fig-
ures 6E, 6F, and 6H). When combined with low-dose morpholi-
nos (3 ng) that resulted in a reduction of approximately 40% in
mekk3 dosage (Figure S7) but had no independent effect on car-
diac development, we observed efficient (75%) rescue of the
krit1 morphant cardiac phenotype (p < 0.001) (Figures 6G and
6H). To ensure that rescue was not due to interference with
krit1 morpholinos, mekk3 morpholinos were injected into em-
bryos generated by ccm2+/ intercrosses. A big heart phenotype
was observed in approximately 18% of control morpholino in-
jected offspring at 72 hpf, and injection of low-dosemekk3mor-
pholinos reduced this to approximately 6%, consistent with a
66% rescue efficiency (p < 0.001, Figure 6I). Thus, loss of
mekk3 rescues the dilated heart phenotype conferred by loss
of either krit1 or ccm2 in zebrafish embryos, suggesting that
gain of MEKK3 signaling may underlie the role of CCM signaling
during cardiac development.
Mekk3 Haplo-Insufficiency Rescues the Loss of Cardiac
Jelly and Changes in Gene Expression Conferred by
Endocardial Krit1 Deletion
Rescue of the big heart phenotype conferred by loss of CCM
signaling with loss of mekk3 expression in the zebrafish requires
careful dosing of mekk3 morpholinos to avoid an independent
mekk3-deficient cardiac defect, and the ability tomeasure rescue
using specificmolecular and cellular endpoints is limited in the ze-
brafish embryo heart. To address these issues and rigorously test
the causal role of the MEKK3 pathway as a downstream CCM
effector in mammals, we next tested the ability of loss of one
Mekk3 allele to rescue the specific changes in cardiac jelly and
cardiac gene expression in the E10.5 Nfatc1Cre;Krit1fl/fl mouse
heart. Despite the expected loss in MEKK3 protein inMap3k3+/
hearts (Figure S6C), Map3k3+/ animals and Nfatc1Cre;
Map3k3fl/+ animals develop normally, exhibit no changes in car-
diac jelly, and have patterns of cardiac gene expression at
E10.5 that are indistinguishable from Map3k3fl/fl littermates
(Yang et al., 2000 and data not shown). Thus, loss of a single
Mekk3 allele iswell tolerated anddoes not affect cardiac develop-
ment. At E10.5, Nfatc1Cre;Krit1fl/fl;Map3k3fl/+ hearts exhibited
significantly more cardiac jelly, Alcian blue staining, and intact
versican than was seen in Nfatc1Cre;Krit1fl/fl;Map3k3+/+ litter-
mates (Figures 7A–7I). Quantitation of the area occupied by car-
diac jelly in the trabeculae of E10.5 littermate hearts revealed a
>65% decrease in Nfatc1Cre;Krit1fl/fl hearts compared with con-
trol littermates, but only a 25% decrease in Nfatc1Cre;Krit1fl/fl;
Map3k3fl/+ hearts (p < 0.001, Figure 7J). Consistent with the
rescue of cardiac jelly, biochemical analysis of ADAMTS-proteo-
lyzed versican using anti-DPEAAE antibodies revealed increased
versican breakdown in the Nfatc1Cre;Krit1fl/fl heart that was
restored to normal levels in theNfatc1Cre;Krit1fl/fl;Map3k3fl/+ heart
(Figure 7K). qPCR analysis of cardiac gene expression revealed
significantly reduced levels of Klf2, Klf4, KLF2/4 target genes,
Adamts4 and Adamts5, and Nrg1, and increased levels of Dll4
and Tmem100, in the Nfatc1Cre;Krit1fl/fl;Map3k3fl/+ heart
compared with the Nfatc1Cre;Krit1fl/fl;Map3k3+/+ heart (Figures
7L–7N). The levels of Klf2, Klf4 and Adamts5 gene expression
were not restored to normal in the Nfatc1Cre;Krit1fl/fl;Map3k3fl/+176 Developmental Cell 32, 168–180, January 26, 2015 ª2015 Elseviheart, consistent with the significant but incomplete histologic
rescue. Thus virtually all of the hallmark histologic, biochemical,
and genetic changes observed with endocardial loss of KRIT1
are rescued by endocardial loss of MEKK3, indicating that gain
of MEKK3 signaling plays a central, causal role in the endothelial
phenotype conferred by loss of CCM signaling in the developing
heart.
DISCUSSION
Genetic studies in humans, mice, and fish have revealed that
CCM signaling is required in endothelial cells for normal cardio-
vascular development and to prevent vascular malformations
after birth, but the molecular basis for these phenotypes has re-
mained elusive. We have used studies of cultured endothelial
cells, endocardial-specific deletion in the developing mouse,
and genetic rescue of the CCM-deficient heart phenotype in
both mice and zebrafish to reveal a molecular mechanism by
which the CCM pathway regulates endothelial gene expression.
Our studies demonstrate that CCM signaling in the endocardium
plays a critical and conserved role in cardiac development
through regulation of the MEKK3 MAPK signaling pathway and
downstream ADAMTS and KLF gene expression.
A role for CCM signaling in cardiac development was revealed
by the dilated heart phenotype observed in zebrafish embryos
lacking this pathway (Mably et al., 2003, 2006; Zheng et al.,
2010), but the molecular and cellular basis for this phenotype
has been unclear. The studies reported here demonstrate that
CCM signaling controls degradation of cardiac jelly by negatively
regulating endocardial expression of ADAMTS4/5 and KLF2/4. A
causal role for excess ADAMTS4/5 is demonstrated by a dra-
matic increase in versican cleavage associated with loss of car-
diac jelly in the Nfatc1Cre;Krit1fl/fl mouse heart and by rescue of
the zebrafish dilated heart with morpholinos that reduced
adamts5 levels. Expression of both Adamts and Klf genes is
severely reduced following endothelial loss of MEKK3 in vitro
and in vivo, increased MEKK3 drives expression of both genes
in cultured endothelial cells, rescue of krit1 morphant and
ccm2 mutant zebrafish hearts was highly efficient with loss of
mekk3, klf2, or adamts5, and both the histologic and molecular
phenotypes conferred by loss of endocardial CCM signaling
are rescued by partial loss of MEKK3. Thus a straightforward
pathway is one in which changes in MEKK3 signaling alter
expression of KLF2/4 that in turn controls expression of
ADAMTS4/5 (Figure 7O). However, Adamts5 has not been iden-
tified as a KLF2 target gene in cultured endothelial cells (Dekker
et al., 2002; Parmar et al., 2005), and we do not detect Adamts5
expression in HUVEC. Thus, Adamts4/5 may be regulated by
MEKK3 in a KLF-independent manner, or by KLF2/4 in embry-
onic endocardium but not in cultured endothelial cells. It is also
likely that MEKK3-regulated and KLF-regulated genes other
than Adamts4/5 contribute to the cardiac phenotype associated
with CCM deficiency. Two such candidates identified by our
gene expression studies are Dll4, a Notch ligand expressed by
the endocardium that supports trabeculation and myocardial
proliferation (Grego-Bessa et al., 2007), and Tmem100, an
ALK1 target gene that is also specifically expressed in the endo-
cardium and required for cardiac growth (Somekawa et al.,
2012). In this regard, it is intriguing that KLF4 has recently beener Inc.
Figure 7. Reduced Mekk3 Expression Res-
cues the Loss of Cardiac Jelly and Changes
in Gene Expression Conferred by Endocar-
dial Loss of Krit1
(A–C) The endocardial-myocardial space occu-
pied by cardiac jelly is increased in Nfatc1Cre;
Krit1fl/fl;Map3k3fl/+ hearts compared with
Nfatc1Cre;Krit1fl/fl;Map3k3+/+ littermates at E10.5.
Higher magnification images of the boxed regions
are shown on the right.
(D–F) Alcian blue staining for cardiac jelly is
increased in Nfatc1Cre;Krit1fl/fl;Map3k3fl/+ hearts
compared with Nfatc1Cre;Krit1fl/fl;Map3k3+/+ lit-
termates at E10.5.
(G–I) Versican in cardiac jelly is increased in
Nfatc1Cre;Krit1fl/fl;Map3k3fl/+ hearts compared
with Nfatc1Cre;Krit1fl/fl;Map3k3+/+ littermates at
E10.5.
(J) The ratio of the area occupied by cardiac jelly to
that occupied by myocardium in the trabeculae is
increased in E10.5 Nfatc1Cre;Krit1fl/fl;Map3k3fl/+
hearts compared with Nfatc1Cre;Krit1fl/fl;
Map3k3+/+ littermates. N = 3 embryos; nine sec-
tions analyzed for each group. Error bars indicate
SEM.
(K) Immunoblot analysis of lysate derived from
whole E10.5 hearts reveals higher levels of
cleaved versican (DPEAAE) in Nfatc1Cre;Krit1fl/fl;
Map3k3+/+ hearts compared withNfatc1Cre;Krit1fl/fl;
Map3k3fl/+ littermates. GAPDH is shown as a
loading control.
(L–N) qPCR of E10.5 hearts reveals normalized
expression of Klf2, Klf4, KLF2/4 target genes,
Nrg1, Dll4, Tmem100, Adamts4 and Adamts5 in
Nfatc1Cre;Krit1fl/fl;Map3k3fl/+ hearts compared
with Nfatc1Cre;Krit1fl/fl;Map3k3+/+ littermates at
E10.5. *p < 0.05; **p < 0.01; ***p < 0.001. Scale
bars represent 100 mm. Error bars indicate SEM.
(O) CCM regulation of MEKK3 activity and gene
expression. The CCM complex binds MEKK3
through interaction with CCM2 and blocks MEKK3
signaling (left). Loss of the CCM complex in-
creases MEKK3-ERK5 signaling and the expres-
sion of Klf2 and Adamts5, resulting in the break-
down of cardiac jelly and reduced myocardial
proliferation (right).shown to repress DLL4 expression in endothelial cells (Hale
et al., 2014).
A key finding to emerge from our studies is the identification of
amolecularmechanism bywhich CCMsignaling regulates endo-
thelial gene expression. Previous studies of the CCM pathway
have not revealed a molecular path to transcriptional regulation,
although changes in RhoA activity (Glading et al., 2007; Stockton
et al., 2010; Whitehead et al., 2009; Zheng et al., 2010) and TGFb
signaling (Maddaluno et al., 2013) have been reported. The find-
ings that CCM2 interacts with MEKK3 in endothelial cells and
that endocardial loss of CCM signaling and MEKK3 confer pre-
cisely reciprocal changes in gene expression suggested that
the CCM pathway may control gene expression by regulatingDevelopmental Cell 32, 168–180MEKK3 signaling (Figure 7O). Rescue of
CCM-deficient phenotypes in cultured
endothelial cells and fish and mouse em-bryos demonstrates a clear causal role for increased MEKK3
function. Previous studies have linked MEKK3 to three down-
streamMAPK pathways by which it might regulate gene expres-
sion: JNK (Deacon and Blank, 1999), p38 (Deacon and Blank,
1999; Uhlik et al., 2003), and ERK5 (Chao et al., 1999; Nakamura
and Johnson, 2003). However, our endothelial studies demon-
strate MEKK3 regulation of KLF2/4 and ADAMTS4 expression
in response to fluid flow, known to be downstream of MEK5
and ERK5 (Li et al., 2008; Parmar et al., 2006; Sohn et al.,
2005), and ex vivo embryonic heart culture studies using a highly
specific MEK5 inhibitor identify the MEK5-ERK5 pathway as a
key mechanism of gene regulation by CCM signaling (Figure 5).
Thus, our studies support a mechanism in which CCM signaling, January 26, 2015 ª2015 Elsevier Inc. 177
specifically regulates the MEK5-ERK5 pathway downstream of
MEKK3 in endothelial cells.
A final question raised by our studies is whether regulation of
the MEKK3 pathway by CCM signaling observed in the devel-
oping heart also plays an important role in the formation of
CCMs in humans and mice. Loss of CCM signaling in the
postnatal endothelium results in large vascular malformations
(CCMs) in the CNS of humans andmice (Akers et al., 2009; Boul-
day et al., 2011; Chan et al., 2011; McDonald et al., 2011). CCMs
are an important cause of stroke for which there is presently no
medical treatment (Li and Whitehead, 2010). Drugs that inhibit
RhoA and TGFb signaling have been reported to reduce lesion
frequency in mouse models of CCM (Maddaluno et al., 2013;
McDonald et al., 2012), but the responses have been incomplete
and a clear molecular and/or cellular basis for CCM formation is
still lacking. Significantly, upregulation of KLF4 expression was
recently identified as a prominent molecular phenotype of the
endothelial cells that form CCMs (Maddaluno et al., 2013), a
finding that mirrors the increase in KLF4 observed in the devel-
oping endocardium and in cultured endothelial cells lacking
CCM signaling. It is therefore possible that CCM-deficient endo-
thelial cells in the CNS exhibit increased MEKK3 activity like that
we have observed in CCM-deficient endocardial cells, and that
changes in gene expression resulting from increasedMEKK3 ac-
tivity also underlie CCM disease pathogenesis. Future studies
that test rescue of CCM formation in mice using either genetic
or pharmacologic loss of MEKK3 pathway activity should be
able to test this clinically important hypothesis.
EXPERIMENTAL PROCEDURES
Mice
Nfatc1Cre (Wu et al., 2012),Ccm2fl/fl (Zheng et al., 2012),Pdcd10fl/fl (Chan et al.,
2010), and Krit1fl/fl(Mleynek et al., 2014) animals have been previously
described. The ROSA26-YFP reporter line was obtained from Jackson Labo-
ratories (#006148).Map3k3fl/fl animals were generated as shown in Figure S6.
The University of Pennsylvania Institutional Animal Care and Use Committee
approved all animal protocols.
Histology
Embryos and tissues were fixed in 10% formaldehyde overnight, dehydrated
in 100% ethanol, and embedded in paraffin. Eight micrometer thick sections
were used for H&E, Alcian blue, and immunohistochemistry staining. Klf2
in situ hybridization was performed as previously reported (Lee et al., 2006).
The following antibodies were used for immunostaining: rat anti-Pecam
(1:500, BD PharMingen), rabbit anti-Versican (1:200, Millipore), and rabbit
anti-DPEAAE (1:200, Pierce-Antibodies).
Zebrafish Studies
Zebrafish were maintained and with approval of the Institutional Animal Care
andUseCommittee of the University of Pennsylvania. ccm2hi296mutant zebra-
fish were obtained from the Zebrafish International Resource Center (ZIRC).
i-fabp:GFP transgenic embryos in which the heart is fluorescently labeled
were kindly provided by Dr. Michael Pack. The cardiac reporter zebrafish
were created by transposon-based gene trap approach using the 192 base
pair zebrafish I-FABP promoter (Her et al., 2004). Morpholino oligonucleotides
were obtained from Gene Tools and were injected into the yolk of one-cell
stage embryos at the indicated dosages and combinations. The morpholino
sequences are described in the Supplemental Experimental Procedures.
Biochemical Studies
Biochemical studies of E10.5 Nfatc1Cre;Krit1fl/fl hearts were performed as pre-
viously described (Kleaveland et al., 2009; Zheng et al., 2010). The following178 Developmental Cell 32, 168–180, January 26, 2015 ª2015 Elseviantibodies were used for immunonlotting: rabbit anti-Gapdh (1:5,000, Cell
Signaling), rabbit anti-pERK5 (1:1,000, Cell Signaling), rabbit anti-Adamts5
(1:1,000, Abcam), and rabbit anti-DPEAAE (1:1,000, Pierce-Antibodies). Iden-
tification of BirA-MEKK3 interacting proteins is described in the Supplemental
Experimental Procedures.
Endothelial Cell Studies
HUVECs (Lonza) were grown in endothelial basal medium supplemented with
EGM-2 SingleQuots (Lonza). HUVECs were transfected overnight with 10 nM
Ambion Silencer Select siRNA against Map3k3 (s8671, Invitrogen) or Ccm2
(s8671, Invitrogen) using siPORT Amine Transfection Agent (Invitrogen) ac-
cording to the manufacturer’s protocol. Seventy-two hours after transfection,
total RNAwas isolated using TRIzol Reagent (Invitrogen). cDNAwas generated
from 1 mg total RNA using Superscript III Reverse Transcriptase (Invitrogen).
qPCR was performed in Power SYBR Green PCR Master Mix (Applied Biosci-
ences) using primers described in the Supplemental Experimental Procedures.
Mouse Heart Explant Studies
Hearts from wild-type embryos on mixed background were collected at E10.5
and cultured in the presence of BIX02189 (5 uM) or DMSO for 24 hr on transwell
filters as described previously (Lavine et al., 2005).
Statistics
p Values were calculated using an unpaired 2-tailed Student’s t test, ANOVA,
or chi-square analysis as indicated. The mean and SEM are shown in the bar
graphs.
SUPPLEMENTAL INFORMATION
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seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.devcel.2014.12.009.
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